ATE453665T1 - Mage-a1 peptide die von klasse ii hla molekule presentiert werden - Google Patents

Mage-a1 peptide die von klasse ii hla molekule presentiert werden

Info

Publication number
ATE453665T1
ATE453665T1 AT00942795T AT00942795T ATE453665T1 AT E453665 T1 ATE453665 T1 AT E453665T1 AT 00942795 T AT00942795 T AT 00942795T AT 00942795 T AT00942795 T AT 00942795T AT E453665 T1 ATE453665 T1 AT E453665T1
Authority
AT
Austria
Prior art keywords
mage
class
hla molecules
peptides presented
seq
Prior art date
Application number
AT00942795T
Other languages
English (en)
Inventor
Snick Jacques Van
Bernard Lethe
Pascal Chaux
Thierry Boon-Falleur
Der Bruggen Pierre Van
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE453665T1 publication Critical patent/ATE453665T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/828—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00942795T 1999-06-18 2000-06-14 Mage-a1 peptide die von klasse ii hla molekule presentiert werden ATE453665T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/336,091 US7157091B1 (en) 1999-06-18 1999-06-18 MAGE-A1 peptides presented by HLA class II molecules
PCT/US2000/016287 WO2000078806A1 (en) 1999-06-18 2000-06-14 Mage-a1 peptides presented by hla class ii molecules

Publications (1)

Publication Number Publication Date
ATE453665T1 true ATE453665T1 (de) 2010-01-15

Family

ID=23314524

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00942795T ATE453665T1 (de) 1999-06-18 2000-06-14 Mage-a1 peptide die von klasse ii hla molekule presentiert werden

Country Status (9)

Country Link
US (1) US7157091B1 (de)
EP (1) EP1224216B1 (de)
JP (2) JP2003502079A (de)
KR (1) KR20020026461A (de)
CN (1) CN100354305C (de)
AT (1) ATE453665T1 (de)
AU (1) AU778449B2 (de)
DE (1) DE60043620D1 (de)
WO (1) WO2000078806A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules
EP1390387A4 (de) * 2001-04-20 2004-12-08 Ludwig Inst Cancer Res Hodenkrebsantigene
US7049413B2 (en) * 2001-05-18 2006-05-23 Ludwig Institute For Cancer Research MAGE-A3 peptides presented by HLA class II molecules
US20030148973A1 (en) * 2001-05-23 2003-08-07 Peter Emtage MAGE-A1 peptides for treating or preventing cancer
US7758892B1 (en) * 2004-05-20 2010-07-20 Boston Scientific Scimed, Inc. Medical devices having multiple layers
CA2571168A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
BRPI0608281B8 (pt) * 2005-04-18 2021-05-25 Amgen Res Munich Gmbh anticorpo monoclonal humano ou seu fragmento, seu uso no tratamento de doenças inflamatórias, bem como composição farmacêutica que o compreende
ES2709176T3 (es) * 2006-08-11 2019-04-15 Life Sciences Res Partners Vzw Péptidos inmunogénicos y su uso en trastornos inmunitarios
WO2008053573A1 (fr) * 2006-10-30 2008-05-08 National University Corporation Hokkaido University Remède pour néoplasme malin
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 Ｔ細胞レセプターβ鎖遺伝子及びα鎖遺伝子
TWI526219B (zh) 2008-06-19 2016-03-21 腫瘤療法 科學股份有限公司 Ｃｄｃａ１抗原決定位胜肽及含此胜肽的疫苗
GB0905519D0 (en) * 2009-03-31 2009-05-13 Biofortuna Ltd Assay method and device
AU2012302778B2 (en) * 2011-08-31 2016-11-24 Mie University Vaccine preparation for cancer treatment
EP2872532A4 (de) 2012-07-10 2016-04-13 Oncotherapy Science Inc Cdca1-epitoppeptide für th1-zellen und impfstoffe damit
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1
NL2014935B1 (en) * 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
KR20180117227A (ko) 2016-03-24 2018-10-26 난트셀, 인크. 네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들
DK3440106T3 (da) * 2016-04-08 2021-10-04 Adaptimmune Ltd T-cellereceptorer
CN106084042B (zh) * 2016-06-24 2020-01-14 安徽未名细胞治疗有限公司 一种全人源抗MAGEA1的全分子IgG抗体及其应用
US11779637B2 (en) * 2017-04-24 2023-10-10 Nantcell, Inc. Targeted neoepitope vectors and methods therefor
CN108948184B (zh) * 2017-05-22 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别衍生自prame抗原短肽的t细胞受体
CN109400697B (zh) * 2017-08-17 2021-04-23 香雪生命科学技术（广东）有限公司 一种识别prame抗原短肽的tcr及其相关组合物
TW202023581A (zh) 2018-08-02 2020-07-01 日商腫瘤療法 科學股份有限公司 來自cdca1的胜肽及含有此的疫苗
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
FR3090319A1 (fr) 2018-12-21 2020-06-26 Commissariat A L'energie Atomique Et Aux Energies Alternatives Melanges d’epitopes t cd8+ immunogenes de la cycline b1
EP3714941A1 (de) 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4-tcrs
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
CA3139011A1 (en) 2019-05-08 2020-11-12 Medigene Immunotherapies Gmbh Engineered t cells
TWI869426B (zh) * 2019-07-30 2025-01-11 大學健康網絡 Ｔ細胞受體及其使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541104A (en) 1991-05-23 1996-07-30 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1
US5405940A (en) 1992-08-31 1995-04-11 Ludwig Institute For Cancer Research Isolated nonapeptides derived from MAGE genes and uses thereof
US6222012B1 (en) * 1992-08-31 2001-04-24 Ludwig Institute For Cancer Research Isolated nonapeptides presented by HLA molecules, and uses thereof
JPH09502086A (ja) 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
US5585461A (en) 1994-03-24 1996-12-17 Ludwig Institute For Cancer Research Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
US6951917B1 (en) 1995-09-26 2005-10-04 The United States Of America As Represented By The Department Of Health And Human Services MHC-class II restricted melanoma antigens and their use in therapeutic methods
JP2001502315A (ja) * 1996-10-10 2001-02-20 プローブ・インターナショナル ウイルス感染を処置するための組成物および方法
US5965535A (en) * 1997-09-12 1999-10-12 Ludwig Institute For Cancer Research Mage-3 peptides presented by HLA class II molecules
US7157091B1 (en) * 1999-06-18 2007-01-02 Ludwig Institute For Cancer Research MAGE-A1 peptides presented by HLA class II molecules

Also Published As

Publication number Publication date
JP4652390B2 (ja) 2011-03-16
DE60043620D1 (de) 2010-02-11
CN1357006A (zh) 2002-07-03
JP2003502079A (ja) 2003-01-21
AU778449B2 (en) 2004-12-02
US7157091B1 (en) 2007-01-02
CN100354305C (zh) 2007-12-12
AU5736700A (en) 2001-01-09
KR20020026461A (ko) 2002-04-10
WO2000078806A1 (en) 2000-12-28
JP2008109928A (ja) 2008-05-15
EP1224216B1 (de) 2009-12-30
EP1224216A1 (de) 2002-07-24

Similar Documents

Publication Publication Date Title
ATE453665T1 (de) Mage-a1 peptide die von klasse ii hla molekule presentiert werden
CY1113218T1 (el) Υβριδιο και διμερης εκφραση πρωτεϊνων ναϊσσεριας
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
BR0208183A (pt) Peptìdeo modificado por wt1
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1108570T1 (el) Gd3-μιμητικα πεπτιδια
ES2133813T3 (es) Cadenas de lamininas: diagnostico y uso terapeutico.
DE60233532D1 (de) An proteinphosphatase 2a bindende synthetische ode anwendungen
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ATE495247T1 (de) Chromoprotein und fluoroproteine
ATE485386T1 (de) Cysteinhaltiges peptid-tag zur stellenspezifischen konjugation von proteinen
ATE307205T1 (de) Gefrorenes lebensmittel
EA200100700A1 (ru) Гены и белки и их применение
IL142709A0 (en) Novel amino acid sequences, dna encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
EP1117682A4 (de) Peptide
SE9800504D0 (sv) Novel peptide/protein, diagnostic reagent and kit for detection of rickettsiosis
DK0811068T3 (da) Humane DNase I varianter
EA200100314A1 (ru) Пептидные фрагменты холерного экзотоксина в или энтеротоксина в в качестве адъювантов вакцины
ATE427955T1 (de) Zusammensetzungen und verfahren zur erfassung von stress induzierten proteinen
DE69827880D1 (de) Iga1-protease fragment als trägerpeptid
SE9604439D0 (sv) New receptor
WO2002099379A3 (en) Breast homing peptides and methods of identifying same using aminopeptidase p
WO1998056810A3 (de) Humanes protein lus-i, seine herstellung und verwendung
WO2004058812A3 (en) Ribose-phosphate pyrophosphokinase polypeptides and structures

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1224216

Country of ref document: EP